Overview
This single vial combines two growth hormone axis peptides: CJC-1295 without DAC, also known as modified GRF(1-29), a tetrasubstituted GHRH analogue, and ipamorelin, a selective GHS-R1a agonist. The label split of 5/5 indicates 5 mg of each peptide.
Research context
GHRH analogues and ghrelin receptor agonists act through separate receptor pathways. Researchers use the pairing to study how signalling through the GHRH receptor and GHS-R1a interacts in preclinical models of pulsatile growth hormone release.
Specifications
- Form: Lyophilized powder
- Quantity: 10 mg total (5 mg CJC-1295 no DAC, 5 mg ipamorelin)
- Composition: CJC-1295 without DAC 5 mg / ipamorelin 5 mg
- Container: 3 mL glass vial, sealed
- Storage: Minus 20 °C, dry and protected from light
- Documentation: Lot-specific Certificate of Analysis (identity and purity by HPLC-MS), matched to the batch number on the label
For laboratory research use only. Not a drug, food, cosmetic or medical device. Not for human or animal use of any kind. No information on this page is medical advice or dosing guidance.



